La Trobe

Exploring the Public Health and Social Implications of Future Curative Hepatitis B Interventions

Download (298.55 kB)
journal contribution
posted on 2023-05-18, 06:55 authored by John WallaceJohn Wallace, Jacqueline Richmond, J Howell, B Hajarizadeh, Jennifer PowerJennifer Power, Carla TreloarCarla Treloar, PA Revill, B Cowie, S Wang, Mark StooveMark Stoove, A Pedrana, M Hellard
Hepatitis B is a significant global health issue where the 296 million people estimated to live with the infection risk liver disease or cancer without clinical intervention. The World Health Organization has committed to eliminating viral hepatitis as a public health threat by 2030, with future curative hepatitis B interventions potentially revolutionizing public health responses to hepatitis B, and being essential for viral hepatitis elimination. Understanding the social and public health implications of any cure is imperative for its successful implementation. This exploratory research, using semi-structured qualitative interviews with a broad range of professional stakeholders identifies the public health elements needed to ensure that a hepatitis B cure can be accessed by all people with hepatitis B. Issues highlighted by the experience of hepatitis C cure access include preparatory work to reorientate policy settings, develop resourcing options, and the appropriateness of health service delivery models. While the form and complexity of curative hepatitis B interventions are to be determined, addressing current disparities in cascade of care figures is imperative with implementation models needing to respond to the cultural contexts, social implications, and health needs of people with hepatitis B, with cure endpoints and discourse being contested.

Funding

J.W., J.H. and M.H. receive fellowship support from the Australian National Health and Medical Research Council. J.H. is supported by a University of Melbourne Faculty Trust Fellowship. C.T. has received speaker fees from Gilead and Abbvie, and research funding (for an unrelated project) from Merck. P.A.R. received research funding from Gilead Sciences. M.S. receives investigator-initiated funding from Gilead Sciences, AbbVie, and Bristol Myers Squibb for research unrelated to this work. A.P. has received speaker fees from Gilead Sciences and receives funding from Gilead Sciences, AbbVie, and Merck for investigator-initiated research. M.H. has received funding from Gilead Sciences and AbbVie for investigator-initiated research. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.

History

Publication Date

2022-11-17

Journal

Viruses

Volume

14

Issue

11

Article Number

2542

Pagination

14p.

Publisher

MDPI

ISSN

1999-4915

Rights Statement

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Usage metrics

    Journal Articles

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC